Proactive Investors - Run By Investors For Investors

The Hydroponics Company well placed to grow as Canada set to legalise recreational cannabis

Canadian subsidiary Crystal Mountain is expanding its range of hydroponics equipment to meet expected demand.
Woman holding cannabis leaf
The medical cannabis company is vertically integrated from 'Farm to Pharma'.

The Hydroponics Company Ltd (ASX:THC) is well-placed to benefit from the legalisation of recreational cannabis in Canada, which takes effect on Wednesday, October 17, 2018.

From this date it will be legal for adults in Canada to purchase, possess, or grow recreational cannabis, a move welcomed by THC, which intends to be renamed THC Global Group Limited.

The new Canadian policy will allow the company to expand its addressable market as part of its ‘Farm to Pharma’ strategy.

READ: The Hydroponics Company to change name to THC Global Group Limited

THC global CEO Ken Charteris commented from Canada, “This is a historic time to be in Canada, on the eve of legalisation of recreational cannabis.”

Canada is subsidiary’s principal market

THC’s wholly-owned subsidiary, Crystal Mountain, manufactures and distributes hydroponic equipment and supplies, with Canada being its principal market.

Crystal Mountain has expanded its warehouse complex and product range to meet expected demand resulting from the legalisation of recreational cannabis.

Crystal Mountain’s expanded facility in British Columbia, Canada.

“Whilst our focus remains on revenue generation from our global medicinal cannabis operations, our expanding presence in the Canadian market through Crystal Mountain and our partners will enable us to take advantage of the broadening of the Canadian market,” Charteris said.

“THC Global has a vertically integrated strategy, providing both the means to grow cannabis to micro-cultivators and home-growers from Crystal Mountain with a view towards selling cannabis products into the Canadian market.”

Duo promoting THC in Canada

Charteris and Crystal Mountain’s global head Jason Colquhoun are in Canada to promote THC to the investment community and to further develop strategic alliances across its cannabis and hydroponics businesses.

THC’s various partnerships and alliances provide the company with market access to Canada in the medicinal and recreational cannabis sectors and through hydroponics equipment.

The letter is expected to be in high demand, driven by the multitude of new micro-cultivator and home-growers in Canada.

Corporate rebranding

As part of embracing the new opportunities, Crystal Mountain will launch a new website and undertake a corporate rebranding to target Canada’s micro-cultivator and home-grower markets.

THC is also incorporating a new subsidiary, Vertical Canna Inc, which will be used as an investment and operations entity for the company’s expanded Canadian operations over the coming months.

Colquhoun said, “We are excited to be able to expand our operations to take advantage of this new opportunity in Canada.

“Combined with the launch of our new website and additional focus towards the micro-cultivator and home-grow markets, we expect to see great results over the coming quarters.”

READ: The Hydroponics Company imported medicinal cannabis products available to Australian patients

THC is a diversified global medical cannabis business that is vertically integrated from ‘farm to pharma’.

The integration begins with a growing site in northern NSW and a growing, research and development facility in Queensland.

It then flows through to an industry-leading biopharmaceutical manufacturing facility ready for pharma-grade production.

Finally, THC has established international commercial partnerships with global industry leaders across Europe, Middle East, North America and Australia.

View full THC profile View Profile

THC Global Group Ltd Timeline

Related Articles

young girl with allergy
April 29 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use